SCHEMBL3869670

SCHEMBL3869670

COC(=O)c1cccc(-n2ncc3c(N)ncnc32)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.63
HSD17B10 Q99714 2/20 0.63
NPC1 O15118 2/20 0.63
RAB9A P51151 2/20 0.63
HTT P42858 1/20 0.63
BLM P54132 1/20 0.63
NPSR1 Q6W5P4 1/20 0.63
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
RXFP1 Q9HBX9 2/20 0.58
XDH P47989 7/20 0.58
ALDH1A1 P00352 1/20 0.57
EGFR P00533 1/20 0.57
CYP1A2 P05177 1/20 0.57
TSHR P16473 1/20 0.57
CYP2C19 P33261 1/20 0.57
PI4KA P42356 1/20 0.57
PI4K2B Q8TCG2 1/20 0.57
PI4K2A Q9BTU6 1/20 0.57
PI4KB Q9UBF8 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3867527 0.87 KDM4E (0.67) KDM4EHSD17B10NPC1RAB9AHTT
SCHEMBL13799331 0.86 RAB9A (0.63) KDM4EHSD17B10NPC1RAB9AHTT
SCHEMBL13790453 0.86 XDH (0.73) KDM4EHSD17B10NPC1RAB9AHTT
SCHEMBL3867283 0.86 XDH (0.73) KDM4EHSD17B10NPC1RAB9AHTT
SCHEMBL5007660 0.83 MEN1 (0.48) KDM4EHSD17B10NPC1RAB9AHTT
SCHEMBL3875705 0.81 XDH (0.74) KDM4EHSD17B10NPC1RAB9AHTT
SCHEMBL5009194 0.81 MEN1 (0.44) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL13790446 0.80 XDH (0.56) KDM4EHSD17B10NPC1RAB9AHTT
SCHEMBL303757 0.80 CCR1 (0.55) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL13790429 0.79 MEN1 (0.60) KDM4EHSD17B10NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1827444-B1 MNK1 OR MNK2 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2013-05-15 EP disclosed
US-20090163520-A1 MNK1 or MNK2 Inhibitors DEVELOGEN AKTIENGESELLSCHAFT (DE) 2009-06-25 US disclosed
US-20090163520-A1 MNK1 or MNK2 Inhibitors DEVELOGEN AKTIENGESELLSCHAFT (DE) 2009-06-25 US disclosed
US-20090163520-A1 MNK1 or MNK2 Inhibitors DEVELOGEN AKTIENGESELLSCHAFT (DE) 2009-06-25 US disclosed
EP-1746099-A1 Mnk1 or Mnk2 inhibitors DeveloGen Aktiengesellschaft (DE) 2007-01-24 EP disclosed
EP-1746099-A1 Mnk1 or Mnk2 inhibitors DeveloGen Aktiengesellschaft (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163520-A1 MNK1 or MNK2 Inhibitors NEK9, CMPK1, NEK2 KDM4E 2821/4885HSD17B10 3021/4885NPC1 2638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.